Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion type Assertion NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_head.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion description "[Topoisomerase II (TOP2) targeting drugs like doxorubicin and etoposide are frontline chemotherapeutics for a wide variety of solid and hematological malignancies, including breast and ovarian adenocarcinomas, lung cancers, soft tissue sarcomas, leukemias and lymphomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion evidence source_evidence_literature NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion SIO_000772 22900064 NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion wasDerivedFrom befree-20140225 NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.
- NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_assertion wasGeneratedBy ECO_0000203 NP751783.RAeNeXwYhl6pDmBg_4N3JCmJ2O5AJwfZsXlLT77tIR6FM130_provenance.